How much does stem cell therapy actually improve heart function?
The most direct evidence comes from a 2024 prospective study that compared stem cell therapy head-to-head with conventional treatments (medications, surgery, or devices) in 95 heart disease patients. After six months, the stem cell group's left ventricular ejection fraction (LVEF) — the percentage of blood pumped out with each beat — jumped from 30.2% to 43.6%, a 13.4 percentage-point gain. The conventional therapy group only improved from 32.5% to 36.8%, a 4.3-point gain [1]. That means the stem cell group more than tripled the improvement in pumping strength.
A broader 2023 meta-analysis pooling data from multiple phase II/III randomized trials of bone marrow-derived mesenchymal stem cells (BM-MSCs) confirmed this pattern: treatment improved LVEF by an average of 6.37% and increased six-minute walking distance by 27.86 meters compared to controls [2]. While these numbers are meaningful — a 6% LVEF boost can translate to better exercise tolerance and fewer hospitalizations — they also show that the effect is modest and varies from patient to patient.
In a large animal study using pigs (a model very close to human hearts), an inhaled stem cell exosome therapy improved ejection fraction by about 11.7% and fractional shortening by 5.7% at 28 days after a heart attack, along with reducing scar size and thickening the heart wall [4]. This suggests that even non-invasive delivery methods can produce measurable cardiac improvement.
What are the main challenges and limitations?
Despite the promising numbers, stem cell therapy for heart regeneration faces several hurdles. The biggest problem is that injected stem cells often don't stay in the heart long enough to work. A 2025 review notes that low cell retention after transplantation is a key barrier, and researchers are developing biomaterial scaffolds and patches to keep cells in place [7]. For example, a 2022 study tested a collagen/PLGA bimodal patch that held stem cells on the heart surface, allowing them to directly form new muscle and blood vessel cells, leading to full recovery of heart function in animal models [6]. Without such scaffolds, most injected cells wash away or die within days.
Another limitation is that not all stem cell types work equally well. A 2026 preclinical study of adipose-derived stem cells for rotator cuff repair found no benefit in tendon healing — the cells failed to improve strength or tissue quality, likely due to immune rejection and poor retention [3]. This highlights that success in one tissue (heart) doesn't guarantee success in another, and that even for the heart, results depend on the specific cell type, delivery method, and patient condition.
Safety is also a concern. While most studies report no major adverse effects, a 2024 review warns that some positive results in the field have been tainted by fraud or data misinterpretation [5]. Additionally, arrhythmias and graft rejection remain risks with cell-based therapies [8]. The field is moving toward cell-free alternatives like exosomes (tiny vesicles released by stem cells) that carry therapeutic cargo without the risk of rejection or tumor formation [8].
Is stem cell therapy ready for routine use in heart patients?
Not yet. The 2023 meta-analysis concludes that while BM-MSC treatment is effective, it 'requires larger and more robust clinical trials to support its routine use in clinics' [2]. The 2025 review of injectable stem cell therapies states that most research is still in preclinical stages, with only small, early-phase clinical trials completed [7]. Even the promising 2024 head-to-head study was a single-center, 95-patient trial that needs replication in larger, multi-center studies [1].
That said, the trajectory is encouraging. The inhaled exosome therapy (SCENT) has already been tested in both mice and pigs with positive results, and the authors say it 'lays the groundwork for clinical investigation' [4]. Engineered exosomes with better heart-targeting and longer circulation times are in development [8]. For now, stem cell therapy is not a standard treatment — it's available only in clinical trials or specialized centers, and patients should discuss risks and benefits with their cardiologist.
Sources used in this answer
Comparison of Conventional Therapies With Stem Cell Therapy in the Treatment of Heart Disease.
In a 2024 head-to-head study of 95 patients, stem cell therapy improved left ventricular ejection fraction (LVEF) from 30.2% to 43.6% after six months, compared to a smaller increase from 32.5% to 36.8% with conventional therapy, and reduced hospitalization rates (10.6% vs 27.1%).
Bone Marrow Mesenchymal Stem Cells for Heart Failure Treatment: A Systematic Review and Meta-Analysis
A 2023 meta-analysis of phase II/III trials found that bone marrow mesenchymal stem cells improved LVEF by 6.37% and six-minute walking distance by 27.86 meters compared to controls.
Preclinical Safety and Efficacy of an Allogeneic Adipose-Derived Mesenchymal Stem Cell Medicinal Product for Rotator Cuff Repair: A Two-Phase Experimental Study.
A 2026 preclinical study of adipose-derived stem cells for rotator cuff repair found no significant improvement in histological score or biomechanical strength, despite a favorable safety profile.
Inhalable Stem Cell Exosomes Promote Heart Repair After Myocardial Infarction
In a 2024 study, inhaled stem cell exosomes (SCENT) improved ejection fraction by 11.66% and fractional shortening by 5.72% in pigs 28 days after myocardial infarction, with reduced infarct size.
Stem Cell Therapy against Ischemic Heart Disease
A 2024 review notes that stem cells from various sources (bone marrow, adipose, induced pluripotent) show therapeutic potential in ischemic heart disease, but warns that some positive results may stem from fraud or data misinterpretation.
Stem cell laden nano and micro collagen/PLGA bimodal fibrous patches for myocardial regeneration
A 2022 study showed that a collagen/PLGA bimodal patch loaded with bone marrow stem cells improved heart function and attenuated remodeling in animal models by enhancing long-term cell retention.
Injectable Stem Cell-Based Therapies for Myocardial Regeneration: A Review of the Literature
A 2025 review states that injectable stem cell therapies for myocardial regeneration are mostly preclinical, with low cell retention as a key challenge, and that biomolecular strategies are being developed to address this.
Cardiac repair and regeneration: cell therapy, in vivo reprogramming, and the promise of extracellular vesicles
A 2025 review highlights that stem-cell-derived extracellular vesicles (exosomes) are nonimmunogenic and reduce inflammation, apoptosis, and infarct size in animal models, offering a promising cell-free alternative to cell therapy.